Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, New England Journal of Medicine, vol.357, issue.25, pp.2562-2575, 2007. ,
DOI : 10.1056/NEJMoa067411
Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study, The Lancet, vol.359, issue.9308, pp.741-746, 2002. ,
DOI : 10.1016/S0140-6736(02)07875-3
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-152, 2009. ,
DOI : 10.1097/FTD.0b013e318198d092
Pharmacogenetics in Kidney Transplantation, Molecular Diagnosis & Therapy, vol.17, issue.4, pp.331-345, 2012. ,
DOI : 10.1007/s40291-012-0012-5
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12, Transplantation, vol.76, issue.8, pp.1233-1235, 2003. ,
DOI : 10.1097/01.TP.0000090753.99170.89
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, Clinical Chemistry, vol.57, issue.11, pp.1574-1583, 2011. ,
DOI : 10.1373/clinchem.2011.165613
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-391, 2001. ,
DOI : 10.1038/86882
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks, British Journal of Clinical Pharmacology, vol.7, issue.Suppl. 1, pp.715-728, 2014. ,
DOI : 10.1111/bcp.12253
The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, American Journal of Transplantation, vol.72, issue.5, pp.914-919, 2004. ,
DOI : 10.1177/0091270003043006001
A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation, Am J Transplant, 2015. ,
The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients, Pharmacogenetics and Genomics, vol.22, issue.8, pp.642-645, 2012. ,
DOI : 10.1097/FPC.0b013e3283557c74
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-726, 2010. ,
DOI : 10.1097/00007890-200212150-00002
The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study, Transplantation, vol.87, issue.9, pp.1360-1366, 2009. ,
DOI : 10.1097/TP.0b013e3181a23cb2
Tacrolimusinduced nephrotoxicity and genetic variability: a review, Ann Transplant, vol.17, issue.2, pp.111-121, 2012. ,
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients???A Prospective, Randomized Study, Transplantation, vol.99, issue.10, pp.2158-2166, 2015. ,
DOI : 10.1097/TP.0000000000000708
genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients, Pharmacogenomics, vol.15, issue.16, pp.2011-2024, 2014. ,
DOI : 10.2217/pgs.14.146
Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, Journal of the American Society of Nephrology, vol.23, issue.11, pp.1891-1899, 2012. ,
DOI : 10.1681/ASN.2012030260
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0191
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease., Journal of Clinical Investigation, vol.100, issue.5, pp.1059-1070, 1997. ,
DOI : 10.1172/JCI119616